A5014735011- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Coronary Interventions and Diagnostics
- Pharmaceutical Practices and Patient Outcomes
- Lipoproteins and Cardiovascular Health
- Sepsis Diagnosis and Treatment
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac Arrhythmias and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Blood Coagulation and Thrombosis Mechanisms
- Diagnosis and Treatment of Venous Diseases
- Cardiac Imaging and Diagnostics
- Blood Pressure and Hypertension Studies
- Inflammatory mediators and NSAID effects
- Cholinesterase and Neurodegenerative Diseases
- Cardiac Valve Diseases and Treatments
- Diabetes Treatment and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac electrophysiology and arrhythmias
- Innovations in Medical Education
- Pharmacogenetics and Drug Metabolism
- Medication Adherence and Compliance
University of Nebraska Medical Center
2015-2025
Nebraska Medical Center
2010-2024
University of Nebraska at Omaha
2010-2023
American College of Clinical Pharmacy
2006-2023
University of North Carolina at Pembroke
2016-2023
Iowa City Public Library
2023
Froedtert Hospital
2021
Medical College of Wisconsin
2021
IS practice
2008-2020
Clinical Research Management
2017
Thrombotic events are commonly reported in critically ill patients with COVID-19. Limited data exist to guide the intensity of antithrombotic prophylaxis.To evaluate effects intermediate-dose vs standard-dose prophylactic anticoagulation among COVID-19 admitted intensive care unit (ICU).Multicenter randomized trial a 2 × factorial design performed 10 academic centers Iran comparing (first hypothesis) and statin therapy matching placebo (second hypothesis; not this article) adult ICU Patients...
Abstract Background Thrombotic complications are considered among the main extrapulmonary manifestations of coronavirus disease 2019 (COVID-19). The optimal type and duration prophylactic antithrombotic therapy in these patients remain unknown. Methods This article reports final (90-day) results Intermediate versus Standard-dose Prophylactic anticoagulation In cRitically-ill pATIents with COVID-19: An opeN label randomized controlled trial (INSPIRATION) study. Patients COVID-19 admitted to...
Well-designed studies with sufficient sample size comparing andexanet alfa vs 4-factor prothrombin complex concentrate (4F-PCC) in routine clinical practice to evaluate outcomes are limited.To compare in-hospital mortality patients hospitalized rivaroxaban- or apixaban-related major bleeding who were treated 4F-PCC.An observational cohort study (ClinicalTrials.gov identifier: NCT05548777) was conducted using electronic health records between May 2018 and September 2022 from 354 U.S....
The platelet P2Y 12 receptor has proved an effective target for therapeutic inhibition of arterial thrombosis, as demonstrated by the significant reductions in cardiovascular events patients receiving thienopyridine agents ticlopidine and clopidogrel. However, limitations these drugs have led to development alternative antiplatelet including prasugrel (CS‐747), oral with a rapid onset action, consistent activity, prolonged duration effect. Prasugrel is prodrug that metabolized one active...
Study Objective. To evaluate the effect of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) on mortality in patients with severe sepsis. Design. Retrospective cohort study. Setting. Intensive care unit (ICU) an academic medical center. Patients. One hundred eighty‐eight aged 40 years or older a diagnosis sepsis and ICU stay between January 1, 2005, December 31, 2006. Measurements Main Results. Patient demographic data, statin use, Acute Physiology Chronic Health...
The 7th conference of the American College Chest Physicians (ACCP7) provides recommendations on type, dose, and duration thromboprophylaxis in hospitalized patients at risk venous thromboembolism (VTE), but extent to which hospitals follow these criteria has not been well studied. Discharge billing records for admitted any 16 acute-care from January 2005 December 2006 were obtained. Patients 18 years or older who had an inpatient stay >or=2 days no apparent contraindications grouped into...
Aim: We describe the real-world utilization and outcomes associated with managing oral factor Xa inhibitor (FXai)-related major bleeds. Materials & methods: Electronic records from 45 US hospitals were queried (ICD-10-CM billing codes D68.32, T45.515x or T45.525x) to identify bleed hospitalizations related FXai use. Patient demographics, type (intracranial hemorrhage, gastrointestinal, critical compartment, traumatic, other), taken, reversal replacement agents administered (including...
The American College of Chest Physicians (ACCP) recommends unfractionated heparin (UFH) or low-molecular-weight (LMWH) for prevention venous thromboembolism (VTE) in medically ill patients. Despite these recommendations, a previous analysis at our institution revealed low utilization VTE prophylaxis Our objective was to evaluate the effects pharmacy-driven education program on quantity and quality patients.An educational focusing importance patients developed by clinical pharmacists...
With the continuing evolution of pharmacy as a clinical profession, need to prepare well‐trained clinicians beyond knowledge gained from doctor degree program is magnified. Such training afforded by residency programs, which have expanded hospital sites practice settings diverse managed care organizations and public health departments. Although resident benefits intensive program, sponsoring institution also derives many hosting residency. Fundamentally, residents are licensed pharmacists...